Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: Results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study

Cancer

Volumn 107, Issue 3, 2006, Pages 613-619

  Morimoto, Akira ^a   Ikushima, Satoshi ^b   Kinugawa, Naoko ^c   Ishii, Eiichi ^d   Kohdera, Urara ^e   Sako, Masahiro ^f   Fujimoto, Junichiro ^g   Bessho, Fumio ^h   Horibe, Keizo ⁱ   Tsunematsu, Yukiko ^j   Imashuku, Shinsaku ^k  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Saiseikai Kyotofu Hospital   (Japan)

^c SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SAGA UNIVERSITY   (Japan)

^e Nakano Children's Hospital   (Japan)

^f OSAKA GENERAL MEDICAL CENTER   (Japan)

^g NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^h KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^j NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^k Takasago seibu Hospital   (Japan)

more..

Author keywords

Chemotherapy; Langerhans cell histiocytosis; Mortality; Reactivation

Indexed keywords

CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DOXORUBICIN; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CHILD; CHILDHOOD CANCER; CLINICAL PROTOCOL; DIABETES INSIPIDUS; FEMALE; HISTIOCYTOSIS X; HUMAN; INFANT; JAPAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SALVAGE THERAPY; SURVIVAL RATE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; INFANT; JAPAN; MALE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33746290278     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21985     Document Type: Article

References (20)

1. Laman JD, Leenen PJ, Annels NE, Hogendoorn PC, Egeler RM. Langerhans-cell histiocytosis 'insight into DC biology.' Trends Immunol. 2003;24:190-196.
2. Imashuku S, Ikushima S, Hibi S, Todo S. Langerhans cell histiocytosis and hemophagocytic syndrome in Japan; epidemiological studies. Int J Pediatr Hematol Oncol. 1994;1:241-246.
3. Gadner H, Ladisch S. The treatment of Langerhans cell histiocytosis. In: Weitzman S, Egeler RM, editors. Histiocytic Disorders of Children and Adults; Basic Science, Clinical Features and Therapy. Cambridge: Cambridge University Press; 2005:229-253.
4. Donadieu J, Egeler RM, Pritchard J. Langerhans cell histiocytosis: a clinical update. In: Weitzman S, Egeler RM, editors. Histiocytic Disorders of Children and Adults; Basic Science, Clinical Features and Therapy. Cambridge: Cambridge University Press; 2005:95-129.
5. Lahey ME. Histiocytosis X-comparison of three treatment regimens. J Pediatr. 1975;87:179-183.
6. Ceci A, de Terlizzi M, Colella R, et al. Langerhans cell histiocytosis in childhood: results from the Italian Cooperative AIEOP-CNR-H.X '83 study. Med Pediatr Oncol. 1993;21:259-264.
7. Gadner H, Heitger A, Grois N, Gatterer-Menz I, Ladisch S. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group. Med Pediatr Oncol. 1994;23:72-80.
8. Minkov M, Grois N, Heitger A, Potschger U, Westermeier T, Gadner H. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group. Klin Padiatr. 2000;212:139-144.
9. Gadner H, Grois N, Arico M, et al., Histiocyte Society. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr. 2001;138:728-734.
10. Haupt R, Nanduri V, Calevo MG, et al. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer. 2004;42:438-444.
11. Grois N, Prayer D, Prosch H, Lassmann H, CNS LCH Cooperative Group. Neuropathology of CNS disease in Langerhans cell histiocytosis. Brain. 2005;128(Pt 4):829-838.
12. Egeler RM, Neglia JP, Arico M, et al. The relation of Langerhans cell histiocytosis to acute leukemia, lymphomas, and other solid tumors. The LCH-Malignancy Study Group of the Histiocyte Society. Hematol Oncol Clin North Am. 1998;12:369-378.
13. Lahey E. Histiocytosis X-an analysis of prognostic factors. J Pediatr. 1975;87:184-189.
14. Imashuku S, Ishida S, Koike K, et al., Japan LCH Study Group. Cerebellar ataxia in pediatric patients with Langerhans cell histiocytosis. J Pediatr Hematol Oncol. 2004;26:735-739.
15. Titgemeyer C, Grois N, Minkov M, Flucher-Wolfram B, Gatterer-Menz I, Gadner H. Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study. Med Pediatr Oncol. 2001;37:108-114.
16. Egeler RM, de Kraker J, Voute PA. Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated Langerhans cell histiocytosis with organ dysfunction: experience at a single institution. Med Pediatr Oncol. 1993;21:265-270.
17. Minkov M, Grois N, Heitger A, Potschger U, Westermeier T, Gadner H, DAL-HX Study Group. Response to initial treatment of multisystem Langerhans cell histiocytosis: an important prognostic indicator. Med Pediatr Oncol. 2002;39:581-585.
18. Bernard F, Thomas C, Bertrand Y, et al. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer. 2005;41:2682-2689.
19. Suminoe A, Matsuzaki A, Hattori H, Ishii S, Hara T. Unrelated cord blood transplantation for an infant with chemotherapy-resistant progressive Langerhans cell histiocytosis. J Pediatr Hematol Oncol. 2001;23:633-636.
20. Steiner M, Matthes-Martin S, Attarbaschi A, et al. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant. 2005;36:215-225.